Cite
HARVARD Citation
Majer, I. et al. (2013). Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial. Journal of medical economics. pp. 1106-1119. [Online].